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Using simply age to screen for cardiovascular disease is as
effective as more complicated methods using blood pressure
and serum cholesterol. That is the main conclusion of a
study published in PloS One in May by Nick Wald, Mark
Simmonds and Joan Morris.
1 I consider here whether the
message is right, what the implications might be and what
we might learn from the prolonged passage to publication
of this paper.
The authors used a Monte Carlo simulation with 500,000
people aged 0–89 to reach their conclusion. Taking being 55
or over as a positive test will detect 86% of cardiovascular
events with a 24% false-positive rate. This simple assess-
ment is compared with screening everybody from age 40
at ﬁve-yearly intervals using the standard Framingham risk
score until people reach the risk of a 20% chance of a cardi-
ovascular event in the next 10 years, the cut-off for treat-
ment recommended by the National Institute of Health
and Clinical Excellence (NICE). For the same 86% detection
rate the false-positive rate is 21%. In other words, the two
methods are effectively the same; almost nothing is gained
from a series of visits to doctors, measurements, and blood
tests.
Can this be right? It is. I write this after reading the com-
ments of 24 reviewers of the paper. None of them seriously
disputes the conclusion. Indeed, many say that the ﬁnding is
unsurprising because, within the Framingham score of risk,
age is so dominant.
The ﬁnding is, however, counterintuitive and contrary to
current perception. Can people’s family history, smoking
status, blood pressure, serum lipids, and weight – all recog-
nized risk factors for cardiovascular disease – not make
much difference? As the paper says, ‘causal CVD risk
factors, even in combination, are poor CVD screening
tests.’
1 Risk factors and screening tests are different. Many
will also wonder why it is that we have a whole industry
of screening tests – not only Framingham but also the
Reynolds risk score
2 or QRISK2
3 – if age alone is just as
good. There is also substantial research effort being applied
to using genetic and other biomarkers to try and predict
more accurately who will have heart attacks and strokes,
research that has had disappointing results.
4
Should we then abandon screening people for risk of
cardiovascular events using the various scores and use
simply age? People wouldn’t have to visit doctors for screen-
ing assessments. They wouldn’t have to have blood tests.
They wouldn’t have to try to understand what their
Framingham score meant, and they wouldn’t be divided
into healthy sheep and unhealthy goats. Complicated risk
assessments might end, but risk reduction – encouraging
and helping people to stop smoking, lose weight, increase
physical activity, eat healthier diets, and drink less
alcohol – should continue. Others apart from doctors and
nurses can do this work.
Risk reduction is sensible for everybody, but the point of
risk assessment is to limit treatment to those above a speci-
ﬁed risk. It is well recognized now that it is a person’s
overall risk (so-called ‘global risk’) that should be assessed
and not simply raised blood pressure or serum lipids. One
implication of the new study is that everybody might begin
treatment at 55. This ﬁts with the strategy proposed by
Wald and Law in 2000
5 and in 2003 in the BMJ
6 to take a
polypill containing blood pressure lowering drugs, a statin,
and possibly aspirin and folic acid. This remains a controver-
sial idea, although less controversial than when ﬁrst
described. Several companies in India have manufactured
polypills, and two trials have been published showing their
effect on measures like blood pressure and serum lipids.
7,8
So will complicated risk assessments be abandoned?
Perhaps not in the short term as we know that there is a
long lag between evidence and action and as there is too
much vested interest in both conducting the assessments
and trying to devise new ones. Both are industries with
markets to protect. The new evidence, although not surpris-
ing, does strengthen the case for the strategy of offering the
polypill to everybody at 55, but this strategy also threatens
vested interests and traditional thinking. Pharmaceutical
companies see lucrative markets being destroyed. Doctors,
particularly cardiologists, are sensitive to the implicit criti-
cism that their strategy of assessing risk and treating is
unnecessarily complex and overlooks the fact that many car-
diovascular events occur in people without high risk factors,
the ‘prevention paradox’.
9 Public health practitioners fear
the polypill offers a licence to people to avoid healthy life-
styles, although there is every reason for people to
combine the polypill with healthy lifestyles and no reason
not to. Finally, some worry about medicalization, although,
as I’ve argued elsewhere, giving people the pill without
tests is the opposite of medicalization in that those who
take the polypill can avoid falling into the hands of
doctors.
10
One of the aspects of this paper that fascinates me – as a
former editor of the BMJ and a current member of the
board of the Public Library of Science – is its publication
history. A version of the paper was ﬁrst submitted to a
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Journal of Medical Screening 2011 Volume 18 Number 3journal, the BMJ, in March 2009. It was ﬁnally published in
PloS One in May 2011, more than two years after it was ﬁrst
submitted. During that time the paper has been rejected
seven times by four journals, including PloS One at ﬁrst,
and reviewed by 24 reviewers. At a conservative estimate
of two hours per review this is more than a week of aca-
demic time. If the academics are paid at a rate of £50 an
hour, again conservative, the cost is over £2000. That
ﬁgure does not include the editorial costs or the opportunity
costs. The academics might have spent their time doing
something much more valuable than reviewing a paper
that 23 other reviewers had also reviewed.
This long delay and high cost might have been justiﬁed if
what was eventually published was much superior to what
was initially submitted. It’s different, but the central
message that age alone is as good as complex risk assessment
scores is still the same and has not been seriously disputed.
The comments of the reviewers could have been a useful
discussion around the paper, part of the process of digesting
it and deciding its true importance. As it is, their comments
are lost in the memory stores of editorial computers. It is not
clear to me whether the journals rejected the paper because
it was too unsurprising or too radical in its threat to estab-
lished interests or, paradoxically, both.
What is clear is that nothing would have been lost and
much gained if this paper had been published straight
away and the debate over its value had been conducted in
public rather than behind closed doors for over two years
at considerable expense. The evidence, as opposed to the
opinion, on prepublication peer review shows that its effec-
tiveness has not been demonstrated and that it is slow,
expensive, largely a lottery, poor at spotting error, biased,
anti-innovatory (as perhaps in this case), prone to abuse,
and unable to detect fraud.
11 The global cost of peer
review is $1.9 billion
12, and it is a faith-based rather than
evidence-based process, which is hugely ironic when it is
at the heart of science.
My conclusion is that we should scrap prepublication peer
review and concentrate on postpublication peer review,
which has always been the ‘real’ peer review in that it
decides whether a study matters or not. By postpublication
peer review I do not mean the few published comments
made on papers, but rather the whole ‘market of ideas,’
which has many participants and processes and moves like
an economic market to determine the value of a paper.
Prepublication peer review simply obstructs this process –
as happened with this important paper showing that age
alone is enough for screening for cardiovascular disease.
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